PFCS
HRTX icon

Pale Fire Capital SE’s Heron Therapeutics HRTX Stock Holding History

Pale Fire Capital SE’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Sell
2,511,478
-204,850
-8% -$164K 0.08% 35
2026
Q1 		$2.17M Buy
2,716,328
+1,246,673
+85% +$1.44M 0.19% 26
2025
Q4 		$1.91M Buy
1,469,655
+998,465
+212% +$1.23M 0.13% 30
2025
Q3 		$594K Buy
+471,190
New +$747K 0.07% 32

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Pale Fire Capital SE's HRTX Position: Q2 2026 in Review

Pale Fire Capital SE reduced its Heron Therapeutics (HRTX) stake by 7.5% in Q2 2026, selling an estimated $164K and leaving 2,511,478 shares worth $1.07M. The position accounts for 0.08% of the portfolio, ranked #35.

Pale Fire Capital SE first reported a position in HRTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.17M in Q1 2026. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Pale Fire Capital SE held 2,511,478 shares of Heron Therapeutics worth $1.07M as of Q2 2026.
  • Pale Fire Capital SE sold 204,850 Heron Therapeutics shares in Q2 2026, an estimated $164K.
  • Heron Therapeutics made up 0.08% of Pale Fire Capital SE's portfolio in Q2 2026, its #35 holding.
  • Pale Fire Capital SE first reported a position in Heron Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Pale Fire Capital SE's Heron Therapeutics position peaked at $2.17M in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.